Evidence map›Paper›PMID 26078579›Full record

Trial reportWorld journal of gastroenterology2015

Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis.

Yun-Hua Li, Lu-Hua Yang, Kai-Hui Sha, Tong-Gang Liu, Li-Guo Zhang, Xian-Xian Liu

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 12 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 12 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. GengricinInternational journal of molecular sciences · 2024
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Yun-Hua LiYun-Hua Li, Tong-Gang Liu, Li-Guo Zhang, Xian-Xian Liu, Department of Infectious Diseases, Binzhou Medical University Hospital, Binzhou 256603, Shandong Province, China.
Lu-Hua YangYun-Hua Li, Tong-Gang Liu, Li-Guo Zhang, Xian-Xian Liu, Department of Infectious Diseases, Binzhou Medical University Hospital, Binzhou 256603, Shandong Province, China.
Kai-Hui ShaYun-Hua Li, Tong-Gang Liu, Li-Guo Zhang, Xian-Xian Liu, Department of Infectious Diseases, Binzhou Medical University Hospital, Binzhou 256603, Shandong Province, China.
Tong-Gang LiuYun-Hua Li, Tong-Gang Liu, Li-Guo Zhang, Xian-Xian Liu, Department of Infectious Diseases, Binzhou Medical University Hospital, Binzhou 256603, Shandong Province, China.
Li-Guo ZhangYun-Hua Li, Tong-Gang Liu, Li-Guo Zhang, Xian-Xian Liu, Department of Infectious Diseases, Binzhou Medical University Hospital, Binzhou 256603, Shandong Province, China.
Xian-Xian LiuYun-Hua Li, Tong-Gang Liu, Li-Guo Zhang, Xian-Xian Liu, Department of Infectious Diseases, Binzhou Medical University Hospital, Binzhou 256603, Shandong Province, China.
Binzhou Medical University · CNBinzhou University · CNCreative Research Enterprises (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo examine whether poly-unsaturated fatty acid (PUFA) therapy is beneficial for improving nonalcoholic steatohepatitis (NASH).

methodsIn total, 78 patients pathologically diagnosed with NASH were enrolled and were randomly assigned into the control group and the PUFA therapy group (added 50 mL PUFA with 1:1 ratio of EHA and DHA into daily diet). At the initial analysis and after 6 mo of PUFA therapy, parameters of interest including liver enzymes, lipid profiles, markers of inflammation and oxidation, and histological changes were evaluated and compared between these two groups.

resultsAt the initial analysis, in patients with NASH, serum levels of alanine aminotransferase (ALT) and aspartase aminotransferase (AST) were slightly elevated. Triglyceride (TG), total cholesterol (TC) and low-density lipoprotein cholesterol levels, markers of systemic inflammation [C-reactive protein (CRP)] and oxidation [malondialdehyde (MDA)], as well as fibrosis parameters of type IV collagen and pro-collagen type III pro-peptide were also increased beyond the normal range. Six months later, ALT and AST levels were significantly reduced in the PUFA group compared with the control group. In addition, serum levels of TG and TC, CRP and MDA, and type IV collagen and pro-collagen type III pro-peptide were also simultaneously and significantly reduced. Of note, histological evaluation showed that steatosis grade, necro-inflammatory grade, fibrosis stage, and ballooning score were all profoundly improved in comparison to the control group, strongly suggesting that increased PUFA consumption was a potential way to offset NASH progression.

conclusionIncreased PUFA consumption is a potential promising approach for NASH prevention and reversal.

Indexed as

Dietary SupplementsAdultBiomarkersBiopsyChinaDisease ProgressionDocosahexaenoic AcidsEicosapentaenoic AcidFemaleHumansLiverLiver CirrhosisLiver Function TestsMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseBiomarkersDocosahexaenoic AcidsEicosapentaenoic AcidManagementNonalcoholic steatohepatitisPoly-unsaturated fatty acid

Identifiers

PMID26078579
PMCPMC4462743
OpenAlexW2413809816

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.